Choose a model
Each card values Day One Biopharmaceuticals a different way, shown at our starting inputs. Pick one to see and change how it works.
Set your assumptions
Day One Biopharmaceuticals on revenue: sales per share grow and the stock trades at a normal price-to-sales multiple. For companies not yet profitable.
Years to project
Growth of revenue per share
Revenue per share; not enough history; starts at 5%
Exit P/S
Starts at its industry's median P/S
Your desired return
Margin of safety
More
Your buy price
The expected return is measured from it; starts at today's price
How it's worked out
Today's revenue per share
Last twelve months
$0.00
Revenue in 2031
Grows 5.0% a year for 5 years
$0.00
Price in 2031
$0.00 × 3.2 P/S
$0.01
Worth today
÷ 1.10^5: your 10% a year, taken back out
$0.00
Fair value
The most you can pay and still earn 10% a year
$0.00
Buy below
Fair value minus your 25% margin of safety
$0.00
Every rule is on the methodology page.
Outcome
What your assumptions give, and the path from today's price.
Fair value
$0.00
Expected return
Set a buy price
Future price, 2031
$0.01
Buy below
$0.00
Projection
Solid blue: the price at each year end. Dashed blue: from today's price to the 2031 price. Green: from the fair value, rising at your 10% a year to the same end point; buy at or below it and you earn at least that. Every rule is on the methodology page. A model, not a forecast or advice.
Day One Biopharmaceuticals (DAWN) intrinsic value and fair value
The calculator grows one of Day One Biopharmaceuticals's per-share figures (earnings, free cash flow, revenue, book value or dividends) for a few years, puts an exit multiple on it, and discounts the result back at the yearly return you want. The answers below use its starting inputs for DAWN; this is analysis, not investment advice.
Frequently asked
What is Day One Biopharmaceuticals's (DAWN) intrinsic value?+
With Intrinsiqq's starting inputs, Day One Biopharmaceuticals's fair value is about $0.00 a share, based on its revenue per share. That assumes revenue per share of $0.00 grows about 5.0% a year for 5 years, the stock then trades at 3.2 times revenue, and you want a 10.0% yearly return. Every input can be changed on the page; the result is a model, not a forecast.
What growth does the Day One Biopharmaceuticals valuation assume?+
Revenue per share grows about 5.0% a year to start, a default, because there is too little history. The exit multiple starts at its industry's median.
What is a good margin of safety for Day One Biopharmaceuticals?+
A margin of safety is the cushion you want below the fair value before buying, in case the inputs are wrong. The calculator uses 25%, which puts the buy-below price at $0.00. Less predictable businesses deserve a wider cushion, or a higher desired return.
Peers
Pharmaceutical Preparations · Pick stocks to compare with DAWN
Spot a number that looks wrong? Check it in DAWN's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing DAWN
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.